

Striving for innovation in respiratory medicine



Solutions with you in mind

www.almirall.com

Almirall's commitment to research in respiratory diseases

Almirall in respiratory medicine

Almirall is a dynamic, international company that strives for innovation through its innovative products in respiratory medicine. Treatment of airway diseases has been one of Almirall's major areas of focus, and significant human and financial resources are being dedicated to research in this field.

Almirall researches, develops, manufactures and commercialises its own R&D drugs and other licensed drugs, with the aim of improving people's health and wellbeing. The on-going commitment, excellence and creative power of our people, have made Almirall a first-class and fast-growing pharmaceutical company.

Acidinium bromide, an evolution in COPD

Almirall has been built around innovation, with products from our own R&D such as the novel, muscarinic antagonist, *acidinium bromide*, and a novel, dual bronchodilator combination of *acidinium bromide*/formoterol. Both *acidinium bromide* and the combination product are being developed utilizing the **Genuair**® inhaler, which is a novel, multidose dry powder inhaler.

Genuair® inhaler, a revolution for patients



Almirall has strengthened its strategic focus in the respiratory area in partnership with Almirall Sofotec, its R&D Centre of Excellence for Inhalation Technology that has designed and developed the novel, multidose dry powder inhaler: **Genuair**®, which has unique, user-friendly features for patients with respiratory diseases:

- **Genuair**® is a novel MDPI (Multi-dose Dry Powder Inhaler) designed with a feedback system to indicate that the patient has inhaled the dose correctly.
- The **Genuair**® inhaler also incorporates significant safety features such as a visible dose indicator, an anti-double dosing mechanism and an end-of-dose lock-out system to prevent use of an empty inhaler.

Product development pipeline

Two additional New Chemical Entities (NCE's) discovered in Almirall are also in development for respiratory diseases. A once-daily long acting beta agonist (LABA) is being developed as a combination product with an inhaled corticosteroid (ICS) and a recently discovered innovative single molecule, dual-action bronchodilator, muscarinic antagonist and beta agonist (MABA) has also entered development. Both of these products are also being developed in the **Genuair**® inhaler.

Respiratory pipeline

Drug	Therapy class	Preclin.	Phase I	Phase II	Phase III	Registration	Registration application
Eklira® (aclidinium bromide)	Antimuscarinic	COPD					July 2011
Acidinium Bromide + Formoterol (LAS40464)	Antimuscarinic + LABA	COPD					Undisclosed
LAS410171 (LAS100977 + ICS)	OD LABA + ICS	Asthma / COPD					> 2014
LAS190792	MABA	COPD					> 2014

In addition, current efforts in early respiratory research in Almirall are devoted to identifying novel, non-steroidal anti-inflammatory therapies for the treatment of persistent asthma, severe asthma and COPD by both oral and inhaled routes of administration.

Almirall striving for excellence

Almirall's products are currently in over **70 markets**, with direct presence in **12 countries** with own affiliates throughout Europe and Latin America, **3 R&D centres** plus **2 R&D units**, and **5 production centres**.



Almirall **invests more than 15%** of its net sales to R&D and **550 professionals** are devoted to R&D activities, amongst a **worldwide workforce** of about **3.100**.

In short, Almirall has a comprehensive network of resources and infrastructures, with a sound portfolio of products under research, a strong commercial force and an excellent team of people.

If you would like to learn more about *acridinium bromide*, join our satellite symposium on Monday 26th September at 17:15 in room 5.1 at the ERS Congress.

***Acridinium bromide*, a new treatment option in COPD: Improving bronchodilation, symptoms and patients' outcomes.**

Chairman: **Alvar Agusti**

Participants: **Steve Rennard, Bartolome Celli, Paul Jones, Carsten Niederlaender**

- 17:15 - 17:25 h **Introduction**
Alvar Agusti (Spain)
- 17:25 - 17:45 h **Why do we need a new long-acting muscarinic antagonist for the treatment of COPD?**
Stephen Rennard (USA)
- 17:45 - 18:00 h **How can a new multidose dry powder inhaler improve patient outcomes? – The Genuair® inhaler**
Carsten Niederlaender (Germany)
- 18:00 - 18:25 h ***Acridinium bromide*: a new long-acting muscarinic antagonist, effect on lung function**
Bartolome Celli (USA)
- 18:25 - 18:50 h **What is the impact of new therapies on health status?**
Paul Jones (UK)
- 18:50 - 19:05 h **Q&A, Panel discussion**
All
- 19:05 - 19:15 h **Chairman's summary and close**
Alvar Agusti (Spain)